Faeth Therapeutics outlines PIKTOR PI3K-alpha/mTOR inhibitor regimen in corporate presentation

• Faeth outlined its oral PI3K/AKT/mTOR regimen PIKTOR, combining serabelisib with sapanisertib for multi-node pathway blockade.
• Phase 2 endometrial topline data targeted by year-end 2026; interim Phase 1b/2 breast data expected in 2H 2027.
• Endometrial Phase 2 PIK-201 is a single-arm study of about 40 patients, enrolling post-ICI and carboplatin with PAM-pathway mutations.
• Prior Phase 1b endometrial subgroup showed 80% ORR, including 3 complete responses, with median PFS of 11 months.
• Company framed market opportunities at about $15-20 billion in breast cancer, about $2-3 billion in endometrial cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief on September 06, 2026, and is solely responsible for the information contained therein.